Full metadata record

DC Field Value Language
dc.contributor.authorChung, Hye J.-
dc.contributor.authorLee, Myung G.-
dc.date.accessioned2024-01-21T02:30:28Z-
dc.date.available2024-01-21T02:30:28Z-
dc.date.created2021-08-31-
dc.date.issued2006-10-
dc.identifier.issn0142-2782-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/135095-
dc.description.abstractPharmacokinetic parameters of ipriflavone were compared after intravenous (20 mg/kg) and oral (200 mg/kg) administration in control rats and in rats with acute renal failure induced by uranyl nitrate (U-ARF rats). It was expected that the time-averaged nonrenal clearance (Cl-nr) of ipriflavone in U-ARF rats could be significantly slower than in the control rats, since it was reported that ipriflavone was metabolized via the hepatic microsomal cytochrome P450 (CYP) 1A1/2 and 2C11 and the expression and mRNA level of CYP1A2 were not changed, but those of CYP2C11 were decreased in U-ARF rats compared with control rats. Unexpectedly, after intravenous administration in U-ARF rats, the Cl-nr, of ipriflavone was significantly faster than in the controls (40.8 compared with 29.0ml/min/kg). This may be due to an increase in the glucuronide conjugate formation of ipriflavone metabolites in U-ARF rats. After oral administration of ipriflavone in U-ARF rats, the AUC(0-24h) was significantly smaller (194 compared with 295 mu g min/ml) than in the controls. Copyright (c) 2006 John Wiley & Sons, Ltd.-
dc.languageEnglish-
dc.publisherJOHN WILEY & SONS LTD-
dc.subjectPOSTMENOPAUSAL OSTEOPOROSIS-
dc.subjectCYP2E1 INDUCTION-
dc.subjectDOSAGE REGIMENS-
dc.subjectPLASMA-
dc.subjectBONE-
dc.subjectMETABOLITES-
dc.subjectLIVER-
dc.titlePharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate-
dc.typeArticle-
dc.identifier.doi10.1002/bdd.515-
dc.description.journalClass1-
dc.identifier.bibliographicCitationBIOPHARMACEUTICS & DRUG DISPOSITION, v.27, no.7, pp.345 - 351-
dc.citation.titleBIOPHARMACEUTICS & DRUG DISPOSITION-
dc.citation.volume27-
dc.citation.number7-
dc.citation.startPage345-
dc.citation.endPage351-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000241997900005-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusPOSTMENOPAUSAL OSTEOPOROSIS-
dc.subject.keywordPlusCYP2E1 INDUCTION-
dc.subject.keywordPlusDOSAGE REGIMENS-
dc.subject.keywordPlusPLASMA-
dc.subject.keywordPlusBONE-
dc.subject.keywordPlusMETABOLITES-
dc.subject.keywordPlusLIVER-
dc.subject.keywordAuthoripriflavone-
dc.subject.keywordAuthorU-ARF-
dc.subject.keywordAuthorpharmacokinetics-
dc.subject.keywordAuthorrats-
Appears in Collections:
KIST Article > 2006
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE